Royal Sense

Why is Royal Sense Ltd falling/rising?

As of 19-Jul, Royal Sense Ltd's stock price is at 102.68, down 14.79% and significantly underperforming the benchmark Sensex. The stock has seen a year-to-date drop of 46.37% and a 49.96% decline over the past year, with reduced investor interest and high volatility contributing to its bearish trend.

As of 19-Jul, Royal Sense Ltd's stock price is falling, currently at 102.68, reflecting a decrease of 17.82 points or 14.79%. This decline is evident in the stock's performance over various periods, showing a significant year-to-date drop of 46.37% compared to a 8.30% decline in the benchmark Sensex. Over the past year, the stock has fallen by 49.96%, while the Sensex has only decreased by 4.99%. <BR><BR>Today's trading performance indicates that the stock has underperformed its sector by 14.49%. It experienced erratic trading, failing to trade on one day out of the last 20, and reached an intraday low of Rs 102.15, marking a 15.23% decline. The stock has shown high volatility today, with an intraday volatility of 8.24%. Additionally, it is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a bearish trend. <BR><BR>Investor participation has also decreased, with delivery volume on July 16 falling by 61.54% compared to the 5-day average, suggesting reduced interest from investors. Overall, these factors contribute to the ongoing decline in the stock price of Royal Sense Ltd.

Which are the latest news on Royal Sense?

What does Royal Sense do?

Royal Sense Ltd is a micro-cap healthcare services company incorporated on April 6, 2023, previously operated by Rishabh Arora. It has a market cap of INR 57 Cr, a P/E ratio of 8.00, and a return on equity of 18.81%.

Overview:<BR>Royal Sense Ltd operates in the healthcare services industry and is categorized as a micro-cap company.<BR><BR>History:<BR>Royal Sense Limited was incorporated as a Public Limited Company on April 06, 2023. Prior to its incorporation, the business was operated by Promoter Rishabh Arora under various sole proprietorships.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: N/A<BR>Most recent Net Profit: N/A<BR>Market-cap value: INR 57 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 8.00<BR>Industry P/E: 21<BR>Dividend Yield: 0.00%<BR>Debt-Equity: 0.26<BR>Return on Equity: 18.81%<BR>Price-to-Book: 1.51<BR><BR>Contact Details:<BR>Registrar Address: Not available.

How big is Royal Sense?

As of 10th June, Royal Sense Ltd has a market capitalization of 57.00 Cr, classifying it as a Micro Cap company. There is no valid financial data available for the latest four quarters, with the latest annual report showing Shareholder's Funds of 27.74 Cr and Total Assets of 35.56 Cr.

As of 10th June, <BR><BR>Market Cap: Royal Sense Ltd has a market capitalization of 57.00 Cr, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: There is no valid financial data available for the latest four quarters, including Net Sales and Net Profit.<BR><BR>Balance Sheet Snapshot: The latest annual reporting period is March 2025, with Shareholder's Funds amounting to 27.74 Cr and Total Assets totaling 35.56 Cr.

Who are the peers of the Royal Sense?

Peers of Royal Sense include Aspira Pathlab, Choksi Laborator, Bandaram Pharma, Shree Pacetronix, Amkay Products, KMS Medisurgi, N G Industries, and Aakaar Medical. Royal Sense shows excellent growth but has the lowest 1-year return at -57.28%, compared to Aspira Pathlab's highest return of 100.85%.

Peers: The peers of Royal Sense are Aspira Pathlab, Choksi Laborator, Bandaram Pharma, Shree Pacetronix, Amkay Products, KMS Medisurgi, N G Industries, and Aakaar Medical.<BR><BR>Quality Snapshot: Excellent management risk is observed at Royal Sense, Shree Pacetronix, Amkay Products, N G Industries, and Aakaar Medical, while Good management risk is found at Aspira Pathlab, Choksi Laborator, Bandaram Pharma, and the rest. Below Average management risk is noted for KMS Medisurgi. Growth is Excellent at Royal Sense, Good at Choksi Laborator, Bandaram Pharma, Shree Pacetronix, and Aakaar Medical, while Below Average growth is seen at Aspira Pathlab, Amkay Products, KMS Medisurgi, and N G Industries. Average capital structure is present at Aspira Pathlab and Choksi Laborator, while Good capital structure is found at Royal Sense, Bandaram Pharma, Shree Pacetronix, Amkay Products, KMS Medisurgi, N G Industries, and Aakaar Medical.<BR><BR>Return Snapshot: Aspira Pathlab has the highest 1-year return at 100.85%, while Royal Sense has the lowest at -57.28%. This indicates that Royal Sense's performance is significantly below that of Aspira Pathlab. Additionally, KMS Medisurgi, N G Industries, and Shree Pacetronix have negative six-month returns.

When is the next results date for Royal Sense Ltd?

The next results date for Royal Sense Ltd is 25 May 2026.

The next results date for Royal Sense Ltd is scheduled for 25 May 2026.

Is Royal Sense overvalued or undervalued?

As of November 17, 2025, Royal Sense is considered overvalued with a valuation grade of very expensive, reflected in its PE ratio of 19.61 and EV to EBIT ratio of 14.67, despite a 1-year stock return of 10.74% that slightly outperformed the Sensex.

As of 17 November 2025, the valuation grade for Royal Sense has moved from very attractive to very expensive, indicating a significant shift in its market perception. The company is currently considered overvalued. Key ratios include a PE ratio of 19.61, an EV to EBIT ratio of 14.67, and a ROCE of 21.47%. <BR><BR>In comparison to its peers, Royal Sense's PE ratio is notably lower than Elitecon International's staggering 294.38, yet higher than PTC India's attractive 7.56. Additionally, Royal Sense's EV to EBITDA ratio of 14.64 suggests it is trading at a premium relative to the industry. Despite a 1-year stock return of 10.74%, which slightly outperformed the Sensex's 9.50%, the overall valuation metrics indicate that Royal Sense is currently overvalued in the healthcare services sector.

How has been the historical performance of Royal Sense?

Royal Sense experienced significant growth from March 2024 to March 2025, with net sales increasing to 61.73 Cr from 17.80 Cr, and profit after tax rising to 6.33 Cr from 1.59 Cr. Key metrics such as operating profit and cash flow also improved, reflecting strong overall financial performance.

Answer:<BR>The historical performance of Royal Sense shows significant growth from March 2024 to March 2025.<BR><BR>Breakdown:<BR>In the fiscal year ending March 2025, Royal Sense reported net sales of 61.73 Cr, a substantial increase from 17.80 Cr in the previous year. Total operating income mirrored this growth, reaching 61.73 Cr compared to 17.80 Cr in March 2024. The company's total expenditure also rose to 52.85 Cr from 15.53 Cr, primarily driven by an increase in the purchase of finished goods, which rose to 51.18 Cr from 18.78 Cr. Operating profit (PBDIT) increased to 8.96 Cr from 2.30 Cr, resulting in an operating profit margin of 14.39%, up from 12.75%. Profit before tax surged to 8.73 Cr from 2.20 Cr, leading to a profit after tax of 6.33 Cr, compared to 1.59 Cr the previous year, reflecting a PAT margin of 10.25%, up from 8.93%. The company's total assets grew to 35.56 Cr from 20.77 Cr, while total liabilities increased to 35.56 Cr from 20.77 Cr, with total debt rising to 3.26 Cr from 1.60 Cr. Cash flow from operating activities improved to 1.00 Cr from -3.00 Cr, and the closing cash and cash equivalents rose to 11.00 Cr from 8.00 Cr, indicating a positive cash position. Overall, Royal Sense demonstrated strong financial performance and growth across key metrics.

Who are the top shareholders of the Royal Sense?

The top shareholder of Royal Sense is Rishabh Arora, holding 61.5% of the shares, with no pledged promoter holdings. Individual investors own 24.17%, while the highest public shareholder is Manish Kumar (HUF) at 1.87%.

The top shareholders of Royal Sense are primarily the promoters, with Rishabh Arora holding the largest stake at 61.5%. There are no pledged promoter holdings, and mutual funds and foreign institutional investors do not hold any shares in the company. The highest public shareholder is Manish Kumar (HUF), who holds 1.87%. Individual investors collectively own 24.17% of the shares.

What is the technical trend for Royal?

As of June 5, 2025, Royal's technical trend is neutral with mixed signals, showing a shift from mildly bearish to sideways, supported by a bullish weekly MACD and mildly bullish weekly KST, while daily moving averages indicate short-term weakness and the RSI shows no clear direction.

As of 5 June 2025, the technical trend for Royal has changed from mildly bearish to sideways. The weekly MACD is bullish, indicating some positive momentum, while the daily moving averages remain mildly bearish, suggesting short-term weakness. The weekly KST is mildly bullish, which adds some support to the overall stance. However, the RSI shows no signal on both weekly and monthly time frames, indicating a lack of clear direction. Overall, the current technical stance is neutral with mixed signals, reflecting indecision in the market.

Has Royal declared dividend?

No Dividend History Available